Cargando…

Rituximab in Systemic Lupus Erythematosus: Transient Effects on Autoimmunity Associated Lymphocyte Phenotypes and Implications for Immunogenicity

B cell abnormalities are common in systemic lupus erythematosus (SLE), and include expansion of double negative (DN) and age-associated-like B cells (ABC-like). We aimed to investigate rituximab (RTX) effects on DN and ABC-like B-cell subsets and, when possible, also secondary effects on T cells. Fi...

Descripción completa

Detalles Bibliográficos
Autores principales: Faustini, Francesca, Sippl, Natalie, Stålesen, Ragnhild, Chemin, Karine, Dunn, Nicky, Fogdell-Hahn, Anna, Gunnarsson, Iva, Malmström, Vivianne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027571/
https://www.ncbi.nlm.nih.gov/pubmed/35464461
http://dx.doi.org/10.3389/fimmu.2022.826152
_version_ 1784691399115931648
author Faustini, Francesca
Sippl, Natalie
Stålesen, Ragnhild
Chemin, Karine
Dunn, Nicky
Fogdell-Hahn, Anna
Gunnarsson, Iva
Malmström, Vivianne
author_facet Faustini, Francesca
Sippl, Natalie
Stålesen, Ragnhild
Chemin, Karine
Dunn, Nicky
Fogdell-Hahn, Anna
Gunnarsson, Iva
Malmström, Vivianne
author_sort Faustini, Francesca
collection PubMed
description B cell abnormalities are common in systemic lupus erythematosus (SLE), and include expansion of double negative (DN) and age-associated-like B cells (ABC-like). We aimed to investigate rituximab (RTX) effects on DN and ABC-like B-cell subsets and, when possible, also secondary effects on T cells. Fifteen SLE patients, fulfilling the ACR 1982 criteria, starting RTX and followed longitudinally up to two years, were analyzed for B- and T- lymphocyte subsets using multicolor flow cytometry. DN were defined as IgD-CD27- and ABC-like as CD11c+CD21- within the DN gate. Additional phenotyping was performed adding CXCR5 in the B-cell panel. Cellular changes were further analyzed in the context of the generation of anti-drug antibodies (ADA) against RTX and clinical information. The SLE patients were mainly females (86.6%), of median age 36.7 (29.8-49.4) years and disease duration of 6.1 (1.6-11.8) years. Within the DN subset, ABC-like (IgD-CD27-CD11c+CD21-) B cell frequency reduced from baseline median level of 20.4% to 11.3% (p=0.03), at early follow-up. The DN B cells were further subdivided based on CXCR5 expression. Significant shifts were observed at the early follow-up in the DN2 sub-cluster (CD11c+CXCR5-), which reduced significantly (-15.4 percentage points, p=0.02) and in the recently described DN3 (CD11c-CXCR5-) which increased (+13 percentage points, p=0.03). SLE patients treated with RTX are at high risk of developing ADA. In our cohort, the presence of ADA at 6 months was associated with lower frequencies of DN cells and to a more pronounced expansion of plasmablasts at early follow-up. The frequency of follicular helper T cells (T(FH), CD4+PD-1+CXCR5+) and of peripheral helper T cells (T(PH), CD4+PD-1+CXCR5-) did not change after RTX. A sub-cluster of PD-1(high)CD4+ T cells showed a significant decrease at later follow-up compared to early follow-up (p=0.0039). It is well appreciated that RTX transiently influences B cells. Here, we extend these observations to cell phenotypes which are believed to directly contribute to autoimmunity in SLE. We show early transient effects of RTX on ABC-like memory B cells, later effects on PD-1(high) CD4+ cells, and possible implications for RTX immunogenicity. Further insight in such effects and their monitoring may be of clinical relevance.
format Online
Article
Text
id pubmed-9027571
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90275712022-04-23 Rituximab in Systemic Lupus Erythematosus: Transient Effects on Autoimmunity Associated Lymphocyte Phenotypes and Implications for Immunogenicity Faustini, Francesca Sippl, Natalie Stålesen, Ragnhild Chemin, Karine Dunn, Nicky Fogdell-Hahn, Anna Gunnarsson, Iva Malmström, Vivianne Front Immunol Immunology B cell abnormalities are common in systemic lupus erythematosus (SLE), and include expansion of double negative (DN) and age-associated-like B cells (ABC-like). We aimed to investigate rituximab (RTX) effects on DN and ABC-like B-cell subsets and, when possible, also secondary effects on T cells. Fifteen SLE patients, fulfilling the ACR 1982 criteria, starting RTX and followed longitudinally up to two years, were analyzed for B- and T- lymphocyte subsets using multicolor flow cytometry. DN were defined as IgD-CD27- and ABC-like as CD11c+CD21- within the DN gate. Additional phenotyping was performed adding CXCR5 in the B-cell panel. Cellular changes were further analyzed in the context of the generation of anti-drug antibodies (ADA) against RTX and clinical information. The SLE patients were mainly females (86.6%), of median age 36.7 (29.8-49.4) years and disease duration of 6.1 (1.6-11.8) years. Within the DN subset, ABC-like (IgD-CD27-CD11c+CD21-) B cell frequency reduced from baseline median level of 20.4% to 11.3% (p=0.03), at early follow-up. The DN B cells were further subdivided based on CXCR5 expression. Significant shifts were observed at the early follow-up in the DN2 sub-cluster (CD11c+CXCR5-), which reduced significantly (-15.4 percentage points, p=0.02) and in the recently described DN3 (CD11c-CXCR5-) which increased (+13 percentage points, p=0.03). SLE patients treated with RTX are at high risk of developing ADA. In our cohort, the presence of ADA at 6 months was associated with lower frequencies of DN cells and to a more pronounced expansion of plasmablasts at early follow-up. The frequency of follicular helper T cells (T(FH), CD4+PD-1+CXCR5+) and of peripheral helper T cells (T(PH), CD4+PD-1+CXCR5-) did not change after RTX. A sub-cluster of PD-1(high)CD4+ T cells showed a significant decrease at later follow-up compared to early follow-up (p=0.0039). It is well appreciated that RTX transiently influences B cells. Here, we extend these observations to cell phenotypes which are believed to directly contribute to autoimmunity in SLE. We show early transient effects of RTX on ABC-like memory B cells, later effects on PD-1(high) CD4+ cells, and possible implications for RTX immunogenicity. Further insight in such effects and their monitoring may be of clinical relevance. Frontiers Media S.A. 2022-04-08 /pmc/articles/PMC9027571/ /pubmed/35464461 http://dx.doi.org/10.3389/fimmu.2022.826152 Text en Copyright © 2022 Faustini, Sippl, Stålesen, Chemin, Dunn, Fogdell-Hahn, Gunnarsson and Malmström https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Faustini, Francesca
Sippl, Natalie
Stålesen, Ragnhild
Chemin, Karine
Dunn, Nicky
Fogdell-Hahn, Anna
Gunnarsson, Iva
Malmström, Vivianne
Rituximab in Systemic Lupus Erythematosus: Transient Effects on Autoimmunity Associated Lymphocyte Phenotypes and Implications for Immunogenicity
title Rituximab in Systemic Lupus Erythematosus: Transient Effects on Autoimmunity Associated Lymphocyte Phenotypes and Implications for Immunogenicity
title_full Rituximab in Systemic Lupus Erythematosus: Transient Effects on Autoimmunity Associated Lymphocyte Phenotypes and Implications for Immunogenicity
title_fullStr Rituximab in Systemic Lupus Erythematosus: Transient Effects on Autoimmunity Associated Lymphocyte Phenotypes and Implications for Immunogenicity
title_full_unstemmed Rituximab in Systemic Lupus Erythematosus: Transient Effects on Autoimmunity Associated Lymphocyte Phenotypes and Implications for Immunogenicity
title_short Rituximab in Systemic Lupus Erythematosus: Transient Effects on Autoimmunity Associated Lymphocyte Phenotypes and Implications for Immunogenicity
title_sort rituximab in systemic lupus erythematosus: transient effects on autoimmunity associated lymphocyte phenotypes and implications for immunogenicity
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027571/
https://www.ncbi.nlm.nih.gov/pubmed/35464461
http://dx.doi.org/10.3389/fimmu.2022.826152
work_keys_str_mv AT faustinifrancesca rituximabinsystemiclupuserythematosustransienteffectsonautoimmunityassociatedlymphocytephenotypesandimplicationsforimmunogenicity
AT sipplnatalie rituximabinsystemiclupuserythematosustransienteffectsonautoimmunityassociatedlymphocytephenotypesandimplicationsforimmunogenicity
AT stalesenragnhild rituximabinsystemiclupuserythematosustransienteffectsonautoimmunityassociatedlymphocytephenotypesandimplicationsforimmunogenicity
AT cheminkarine rituximabinsystemiclupuserythematosustransienteffectsonautoimmunityassociatedlymphocytephenotypesandimplicationsforimmunogenicity
AT dunnnicky rituximabinsystemiclupuserythematosustransienteffectsonautoimmunityassociatedlymphocytephenotypesandimplicationsforimmunogenicity
AT fogdellhahnanna rituximabinsystemiclupuserythematosustransienteffectsonautoimmunityassociatedlymphocytephenotypesandimplicationsforimmunogenicity
AT gunnarssoniva rituximabinsystemiclupuserythematosustransienteffectsonautoimmunityassociatedlymphocytephenotypesandimplicationsforimmunogenicity
AT malmstromvivianne rituximabinsystemiclupuserythematosustransienteffectsonautoimmunityassociatedlymphocytephenotypesandimplicationsforimmunogenicity